ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 680 full-time employees. The company went IPO on 2015-07-28. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
Follow-Up Questions
Who is the CEO of Immunitybio Inc?
Mr. Richard Adcock is the President of Immunitybio Inc, joining the firm since 2020.
What is the price performance of IBRX stock?
The current price of IBRX is $2.76, it has decreased 2.98% in the last trading day.
What are the primary business themes or industries for Immunitybio Inc?
Immunitybio Inc belongs to Biotechnology industry and the sector is Health Care
What is Immunitybio Inc market cap?
Immunitybio Inc's current market cap is $2.6B
Is Immunitybio Inc a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for Immunitybio Inc, including 4 strong buy, 6 buy, 1 hold, 0 sell, and 4 strong sell
